Regeneron Pharmaceuticals received accelerated FDA approval for Lynozyfic (linvoseltamab), a bispecific antibody targeting BCMA and CD3, for adults with relapsed and refractory multiple myeloma. The approval provides dosing flexibility that differentiates it from competitors by Johnson & Johnson and Pfizer. Continued approval is contingent on confirmatory trials. The approval represents a significant milestone for Regeneron’s oncology portfolio expansion.